Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype

Fig. 4

Peak-centred binding in sites shared by our PR and FOXA1 and upregulation of EGFR and EGF upon estrogen and progesterone treatment. a Overlap of FOXA1 binding sites identified in ZR-75-1 cells by Hurtado et al., with our estrogen pretreated, progesterone treated PR binding sites and our previously identified ERα binding sites. b Alignment of our estrogen pretreated, progesterone treated binding sites with the ZR-75-1 FOXA1 binding sites identified by Hurtado et al. [25]. c Steady state levels by immunoblotting of PR-A, PR-B, ERα and loading control GAPDH after 16 h 10nM progesterone or estrogen and progesterone treatment, with or without 72 h 10nM estrogen pretreatment (E2p). d Validation of up regulation of EGFR and EGF upon 72 h 10nM estrogen pretreatment followed by increasing times of incubation with 10nM progesterone in independently prepared RNA samples

Back to article page